Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results

Abstract

Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.

Intravitreal Bevacizumab for Macular Edema Due to Central Retinal Vein Occlusion: Perfused vs. Ischemic and Early vs. Late Treatment

“…11,[13][14][15]21 However, other studies investigating IVB for CME secondary to CRVO do not report a statistically significant improvement in visual acuity from baseline despite improving edema. [22][23][24][25] We observed a statistically significant decrease in edema at all time points, but noted statistically significant improvement in BCVA only at 1 month, 3 months, and final follow-up. IVB appears …”

Intravitreal Triamcinolone Acetonide Injection for Macular Edema Due to Central Retinal Vein Occlusion Persisting Despite Multiple Intravitreal Bevacizumab Injections

“…5,7 Results to date have been favorable and both ranibizumab and the off-label use of bevacizumab have resulted in improved visual acuity in several large clinical trials and case series. 7,8,[15][16][17][18] Although many patients have decreased macular edema and improved visual acuity with ongoing therapy, a significant number of patients have persistent macular edema despite anti-VEGF therapy.…”

Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion

“…A number of case studies have been performed on intravitreal bevacizumab treatment for CME in CRVO [14][15][16][17][18]. In general, CME and CRT reduced to some extent in all these studies, with variable visual outcome.…”

“…Numerous case series have reported the results of intravitreal bevacizumab injections for macular edema in CRVO, but have not analyzed SMD as a prognostic factor [15][16][17][18][19].…”